Table: Anges -Q1 group results
Apr 22 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2019 Mar 31, 2018 Dec 31, 2019
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 75 mln 73 mln 335 mln
(+2.4 pct) (-11.4 pct) (-45.1 pct)
Operating loss 918 mln loss 590 mln loss 2.80
Recurring loss 938 mln loss 587 mln loss 2.80
Net loss 1.18 loss 537 mln loss 2.80
EPS loss 11.92 yen loss 6.67 yen loss 27.40 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001